Outcomes in chronic lymphocytic leukemia patients on novel agents in the US Veterans Health Administration System. Issue 7 (7th June 2021)

• Record Type: Journal Article
• Authors: Frei, Christopher R.; Le, Hannah; McHugh, Daniel; Ryan, Kellie; Jones, Xavier; Galley, Samantha; Franklin, Kathleen; Baus, Courtney J.; Tavera, Juan; Janania-Martinez, Michelle; Gregorio, David; Ananth, Snegha; Uribe, Ricardo; Surapaneni, Prathibha; Espinoza-Gutarra, Manuel; Song, Michael M.; Teng, Chengwen; Obodozie-Ofoegbu, Obiageri O.; Nooruddin, Zohra
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 7(2021)
• Page Start: 1664
• Page End: 1673
• Publication Date: 2021-06-07
• Subjects: Chronic lymphocytic leukemia -- adverse events -- novel agents -- discontinuation -- dose reduction -- chart review; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2021.1876863
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: The US veteran population has a high proportion of chronic lymphocytic leukemia (CLL) risk factors. Using the Veterans Health Administration (VHA) population, we conducted a retrospective chart review of 1205 CLL patients who initiated treatment with a novel oral agent. For 1L ibrutinib, 33% ( n = 107) discontinued therapy during the study, of which 64% discontinued due to adverse events (AEs). For relapsed/refractory (R/R) ibrutinib, 35% ( n = 262) discontinued therapy, of which 63% discontinued due to AEs. For R/R venetoclax, 31% ( n = 27) discontinued therapy, of which 41% were due to AEs. For idelalisib, 84% ( n = 41) discontinued therapy, of which 54% were due to AEs. This real-world study suggests that AEs play an important role in dose reductions and discontinuations; however, physician inexperience in using these drugs when they were first introduced could be part of what is leading to these negative outcomes.